A clinician in the Department of Microbiology, Haematology, Parasitology and Infectious Diseases in the Faculty of Medicine and Biomedical Sciences at the University of Yaoundé in Cameroon.
A gynecologist, public health specialist, and fellow at the University of Texas MD Anderson Cancer Center.
AMA J Ethics. 2020 Feb 1;22(2):E116-125. doi: 10.1001/amajethics.2020.116.
Molecular detection of high-risk human papillomavirus (HPV) in genital cells is being widely endorsed as a preferred tool for cervical cancer screening globally. In low- and middle-income countries (LMICs) where cervical cancer remains a leading killer, HPV testing is an appealing, accessible alternative to traditional cytology (ie, Pap smear) screening that enables women to self-collect specimens. This article examines self-sampling and its suitability as a strategy for cervical cancer prevention in LMICs that would promote equitable access to cervical cancer screening.
目前，在全球范围内，检测生殖道细胞中的高危型人乳头瘤病毒（HPV）被广泛推荐作为宫颈癌筛查的首选方法。在宫颈癌仍然是主要死因的低收入和中等收入国家（LMICs），HPV 检测是传统细胞学（即巴氏涂片）筛查的一种有吸引力的、可及的替代方法，使女性能够自行采集标本。本文探讨了自我采样及其作为促进宫颈癌筛查公平获取的 LMICs 宫颈癌预防策略的适用性。
